A T cell–based SARS-CoV-2 spike protein vaccine provides protection without antibodies
Open Access
- 23 January 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (5)
Abstract
SARS-CoV-2 spike–based vaccines are used to control the COVID-19 pandemic. However, emerging variants have become resistant to antibody neutralization and further mutations may lead to full resistance. We tested whether T cells alone could provide protection without antibodies. We designed a T cell–based vaccine in which SARS-CoV-2 spike sequences were rearranged and attached to ubiquitin. Immunization of mice with the vaccine induced no specific antibodies, but strong specific T cell responses. We challenged mice with SARS-CoV-2 wild-type strain or an Omicron variant after the immunization and monitored survival or viral titers in the lungs. The mice were significantly protected against death and weight loss caused by the SARS-CoV-2 wild-type strain, and the viral titers in the lungs of mice challenged with the SARS-CoV-2 wild-type strain or the Omicron variant were significantly reduced. Importantly, depletion of CD4 + or CD8 + T cells led to significant loss of the protection. Our analyses of spike protein sequences of the variants indicated that fewer than one-third presented by dominant HLA alleles were mutated and that most of the mutated epitopes were in the subunit 1 region. As the subunit 2 region is conservative, the vaccines targeting spike protein are expected to protect against future variants due to the T cell responses.Keywords
Funding Information
- Norges Idrettshøgskole (R01 AI157975)
- Norges Idrettshøgskole (R01AI139092,from NIH)
This publication has 57 references indexed in Scilit:
- SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to OmicronCell, 2022
- OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fearJournal of Medical Virology, 2021
- A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitopeImmunity, 2021
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesCell, 2021
- A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variantsImmunity, 2021
- A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damageCell Reports, 2021
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraCell, 2021
- A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in MiceImmunity, 2020
- Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in MiceCell Host & Microbe, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020